On August 5, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Institutional investors and analysts are invited to register to attend the in-person session, which will feature a comprehensive overview of Telix’s therapeutic and precision medicine pipeline, as well as key scientific, clinical and strategic developments across the portfolio.
Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer, Dr. David N. Cade; CEO Therapeutics, Richard Valeix; CEO Precision Medicine, Kevin Richardson and Vice President Discovery Sciences, Dr. Michael Wheatcroft. The program will also feature presentations from key opinion leaders who will provide their perspectives on the clinical and scientific opportunities.
Advance registration is required for in-person attendance. Additional event details, including the venue, agenda and presentation materials, will be provided to registered attendees.
To RSVP or inquire about the R&D Day, please contact [email protected] or [email protected].
Capital Markets Day to be hosted in Melbourne on November 4, 2026 – Save the Date
Telix will also host a Capital Markets Day in Melbourne on Wednesday, November 4, 2026. Telix management will provide updates on the Company’s strategy, growth outlook, financial targets and key business priorities. Further details will be provided in a separate announcement.
(Press release, Telix Pharmaceuticals, AUG 5, 2026, View Source [SID1234669760])